Interest of Dosing of Ibrutinib in B-Cell Lymphoid Malignancies: Data from a Real-Life, Phase 4 Study - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue Blood Année : 2018

Interest of Dosing of Ibrutinib in B-Cell Lymphoid Malignancies: Data from a Real-Life, Phase 4 Study

Dates et versions

hal-02348092 , version 1 (05-11-2019)

Identifiants

Citer

Anne Calleja, Sandra de Barros, Camille Vinson, Caroline Protin, Lucie Obéric, et al.. Interest of Dosing of Ibrutinib in B-Cell Lymphoid Malignancies: Data from a Real-Life, Phase 4 Study. Blood, 2018, 132 (Supplement 1), pp.3960-3960. ⟨10.1182/blood-2018-99-116532⟩. ⟨hal-02348092⟩
50 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More